United States · Markets & Finance · Investor's Business Daily

Uniqure Plummets 37% On Another Shocking Twist For Its Huntington's Drug

Published by Investor's Business Daily · United States 1 d ago

Uniqure stock crashed Tuesday on a disappointing four-year update for its gene therapy in patients with Huntington's disease.

Read the full article on Investor's Business Daily Sign in to save

MediaNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.investors.com)

Also worth reading

Pledge signed by President Trump and top AI leaders misspells the United States

Vanguard Short-Term Inflation-Protected Securities ETF declares quarterly distribution of $0.9333

EIA Reports Crude Build as Diesel Stocks Fall 14% Below Average

Private sector jobs rose by 90,000 in September, better than expected, ADP reports

Fed’s Preferred Inflation Gauge Points to Continued Price Pressures

Business Insider

Yes, you are waiting longer for Uber rides, a new study says